---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-23-029792"
form_type: "8-K"
ticker: "LMAT"
cik: "0001158895"
company_name: "LEMAITRE VASCULAR INC"
filed_at: "2023-11-01T23:59:59+00:00"
generated_at: "2026-06-09T02:02:09.381274+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# LeMaitre Q3 sales $47.4M (+21%); EPS $0.33; declares $0.14 dividend; guides Q4 $48-50M

## Summary
- Q3 sales $47.4M (+21% YoY, +16% organic); net income $7.5M (+38%); diluted EPS $0.33 (+36%).
- Gross margin 65.0% (+80 bps); operating income $9.2M (+49%); cash up $6.8M to $97.0M.
- Q4 2023 guidance: sales $48-50M, EPS $0.34-0.38; full-year 2023 EPS $1.30-1.35 (+42% YoY).
- Quarterly dividend $0.14/share, payable Nov 30 to shareholders of record Nov 16.
- Leases for Burlington, MA headquarters extended to Dec 31, 2034 with escalating rent; no renewal options.

## SEC filing metadata
- accession: 0001437749-23-029792
- form_type: 8-K
- ticker: LMAT
- cik: 0001158895
- company_name: LEMAITRE VASCULAR INC
- filed_at: 2023-11-01T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1158895/000143774923029792/0001437749-23-029792-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1158895/000143774923029792/lmat20231101_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-23-029792
- JSON: https://secwatch.observer/filing/0001437749-23-029792.json
- Plain text: https://secwatch.observer/filing/0001437749-23-029792.txt

## Key facts
- Earnings Releases
  LEMAITRE VASCULAR INC reported quarter ended September 30, 2023 results: revenue $47.4mm, net income $7.5mm, EPS $0.33. Guidance initiated.
  - Period: quarter ended September 30, 2023
  - Revenue: $47.4mm
  - Net income: $7.5mm
  - EPS: $0.33
  - Guidance: initiated
  - Result: preliminary results
  source text: of vascular devices, implants and services, today reported Q3 2023 results, announced a $0.14/share quarterly dividend and provided guidance. Q3 2023 Financial Results ● Sales $47.4mm, +21% (+16% organic) vs. Q3 2022 ● Gross margin 65.0%, +80 bps ● Op. income $9.2mm, +49% ● Op. margin 19% ● Net income $7.5mm, +38% ● Earnings per diluted share $0.33, +36% ●
  evidence_url: https://www.sec.gov/Archives/edgar/data/1158895/000143774923029792/0001437749-23-029792-index.htm
- Material Agreements
  LEMAITRE VASCULAR INC amended Amendments (effective 2023-10-18).
  - Action: amendment
  - Agreement: lease
  - Effective: 2023-10-18
  source text: On October 18, 2023, LeMaitre Vascular, Inc. (the “Company”) entered into amendments (“Amendments”) to its leases for its headquarter properties located at 32-34 Third Avenue and 43, 53 and 63 Second Avenue in Burlington, Massachusetts.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1158895/000143774923029792/0001437749-23-029792-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.